Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches
التاريخ
2021-09-01المؤلف
Marei, Hany E.Althani, Asmaa
Afifi, Nahla
Pozzoli, Giacomo
Caceci, Thomas
Angelini, Franco
Cenciarelli, Carlo
...show more authors ...show less authors
البيانات الوصفية
عرض كامل للتسجيلةالملخص
We give a summary of SARS-genetic CoV-2’s structure and evolution, as well as current attempts to develop efficient vaccine and treatment methods for SARS-CoV-2 infection, in this article. Most therapeutic strategies are based on repurposing of existing therapeutic agents used against various virus infections and focused mainly on inhibition of the virus replication cycle, enhancement of innate immunity, and alleviation of CRS caused by COVID-19. Currently, more than 100 clinical trials on COVID-19 aim to provide robust evidence on the efficacy of the currently available anti-SARS-CoV-2 antiviral substances, such as the nucleotide analogue remdesivir, the antimalarial drug chloroquine, and drugs directed against docking of SARS-CoV-2 to the membrane-associated angiotensin-converting enzyme 2 (ACE2) such as transmembrane protease serine 2 (TMPRSS2). The current vaccination campaign is ongoing worldwide using different types of vaccines such as Pfizer-BioNTech and Moderna, Johnson & Johnson, Oxford-AstraZeneca, Novavax, and others with efficacy ranging from 72–95%. In March 2021 Germany limited the use of the Oxford-AstraZeneca COVID-19 vaccine to people 60 years of age and older due to concerns that it may be causing blood clots. Further study and more data are needed to confirm the safety of different available vaccines.
معرّف المصادر الموحد
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85112580652&origin=inwardالمجموعات
- الأبحاث [727 items ]
- أبحاث فيروس كورونا المستجد (كوفيد-19) [811 items ]